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Intracranial VCAM1 at time of mechanical
thrombectomy predicts ischemic stroke
severity
Benton Maglinger1, Madison Sands1, Jacqueline A. Frank1,2, Christopher J. McLouth3, Amanda L. Trout1,2,
Jill M. Roberts2,4,5, Stephen Grupke6, Jadwiga Turchan-Cholewo1,2, Ann M. Stowe1,4,2, Justin F. Fraser1,2,4,5,7 and
Keith R. Pennypacker1,2,4*

Abstract
Background: Emergent large vessel occlusion (ELVO) strokes are devastating ischemic vascular events for which
novel treatment options are needed. Using vascular cell adhesion molecule 1 (VCAM1) as a prototype, the objective
of this study was to identify proteomic biomarkers and network signaling functions that are potential therapeutic
targets for adjuvant treatment for mechanical thrombectomy.
Methods: The blood and clot thrombectomy and collaboration (BACTRAC) study is a continually enrolling tissue
bank and registry from stroke patients undergoing mechanical thrombectomy. Plasma proteins from intracranial
(distal to clot) and systemic arterial blood (carotid) were analyzed by Olink Proteomics for N=42 subjects. Statistical
analysis of plasma proteomics used independent sample t tests, correlations, linear regression, and robust
regression models to determine network signaling and predictors of clinical outcomes. Data and network analyses
were performed using IBM SPSS Statistics, SAS v 9.4, and STRING V11.
Results: Increased systemic (p<0.001) and intracranial (p=0.013) levels of VCAM1 were associated with the presence
of hypertension. Intracranial VCAM1 was positively correlated to both infarct volume (p=0.032; r=0.34) and edema
volume (p=0.026; r=0.35). The %Δ in NIHSS from admittance to discharge was found to be significantly correlated
to both systemic (p=0.013; r = −0.409) and intracranial (p=0.011; r = −0.421) VCAM1 levels indicating elevated levels
of systemic and intracranial VCAM1 are associated with reduced improvement of stroke severity based on NIHSS
from admittance to discharge. STRING-generated analyses identified biologic functional descriptions as well as
function-associated proteins from the predictive models of infarct and edema volume.
Conclusions: The current study provides novel data on systemic and intracranial VCAM1 in relation to stroke
comorbidities, stroke severity, functional outcomes, and the role VCAM1 plays in complex protein-protein signaling
pathways. These data will allow future studies to develop predictive biomarkers and proteomic targets for drug
development to improve our ability to treat a devastating pathology.
Keywords: Vascular cell adhesion molecule 1, Ischemic stroke, Infarct volume, Mechanical thrombectomy,
Biomarkers, Proteomics
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Background
Vascular cell adhesion molecule 1 (VCAM1) mediates
leukocyte-endothelial cell adhesion and has been associated with pathologies such as ischemic stroke [1]. It is
known that cerebrovascular ischemia upregulates
leukocyte-endothelial adhesion molecules [2–6]. Upregulation of these proteins permits inflammatory cells to
adhere to and migrate through the vascular wall. Ischemic events exacerbate tissue injury in part by inducing
endothelial damage allowing leukocytes to extravasate
into brain tissue [7]. Polymorphonuclear leukocytes
(PMNs) aggravate the injured tissue both at the site of
ischemia as well as the peripheral penumbra [8, 9]. This
extravasation process contributes to consequential inflammation and vasogenic edema leading to the worsening of the impact of ischemic insult [10, 11].
The University of Kentucky Center for Advanced
Translational Stroke Science utilizes mechanical
thrombectomy to better understand emergent large vessel occlusion (ELVO) stroke. Following the blood and
clot thrombectomy registry and collaboration (BACTRAC) protocol (clinicaltrials.gov NCT03153683), human tissue samples are banked and subsequently used
for experimentation [12]. This protocol allows for isolation of intracranial (i.e., distal to thrombus) arterial
blood and systemic (i.e., carotid) arterial blood from
thrombectomy procedures. To date, we have studied arterial blood gasses (ABGs), electrolyte chemistry, genomics, neuroinflammation, and proteomics [13–15].
The objective of this study was to assess VCAM1 protein concentrations as a potential biomarker of injury.
We selected VCAM1 as our prototype protein for several reasons. First, VCAM1 is an example of an endpoint
protein downstream from critical proinflammatory signals such as TNFα and IL-6. Secondly, the function of
VCAM1 is particularly relevant to neuroinflammation in
stroke as it acts to permit extravasation of leukocytes
through the vascular wall into brain tissue. Lastly,
VCAM1 is well-reported in the literature in the context
of ischemia, vascular comorbidities, and molecular signaling pathways which allows us to compare our data to
published benchmarks. The first goal was to assess how
intracranial and systemic proteomic expression levels of
VCAM1 differed according to comorbid conditions such
as hypertension (HTN), smoking, and hyperlipidemia.
Second, we investigated the relationships of systemic
and intracranial VCAM1 with metrics of stroke severity
and functional recovery including infarct volume, infarct
edema, infarct time, and National Institute of Health
Stroke Scale/Score (NIHSS). Lastly, we analyzed VCAM1
data in context to related cardiometabolic and inflammatory proteins to elucidate relevant proteomic signaling networks involved in ischemic stroke. One specific
protein relationship studied was interleukin 6 (IL-6) as it
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has been shown to be related to stroke risk factors, infarct volume, and clinical outcomes [16, 17]. These data
will elucidate predictive biomarkers and potential therapeutic targets for the prognostics and treatment of
ELVO patients.

Methods
Sample acquisition and analysis

The BACTRAC program is a continually enrolling human tissue bank and registry (clinic altrials.gov
NCT03153683) of patients undergoing mechanical
thrombectomy (MT) for emergent large vessel occlusion
(ELVO) stroke. The study is approved through the Institutional Review Board (IRB) at the University of Kentucky; written consent is obtained from the subjects or
their legally authorized representative. All non-pregnant
adult (18 or older) thrombectomy candidates were considered for inclusion. The main exclusions occurred due
to patients either being pregnant, imprisoned, or unable
to consent within a 72-h window outlined by the IRB.
While the tissue bank is continuously enrolling, samples
included in the present study were obtained between
June 21, 2017, and August 2, 2020. Methods in which
tissue samples were obtained during thrombectomy have
been previously published [12]. Intracranial and systemic
plasma samples from 42 subjects underwent cardiometabolic and inflammatory proteomic analysis at Olink Proteomics (Olink Proteomics, Boston, MA). We chose
Olink specifically for their well-established methods regarding proteomic analyses on small-volume samples.
This is of particular interest to us as our intracranial
samples are small volume in nature. Olink utilizes a
unique proximity extension assay (PEA) technology and
rather than reporting protein expression in a concentration value, they report a Normalized Protein eXpression
(NPX) value that is a unit in log2 scale which allows for
individual protein analysis across a sample set. Methods
outlining tissue processing and protein isolation has also
been previously published [15]. Demographic data including age, sex, BMI, hypertension, diabetes, hyperlipidemia, previous stroke, previous myocardial infarction,
smoking status, NIHSS on admission, NIHSS on discharge, thrombolysis in cerebral infarction (TICI) score,
computed tomography angiogram (CTA) collateral
score, infarct time, infarct volume, and edema volume
are reported for each subject. The % change in NIHSS
was calculated as ((Admittance NIHSS − Discharge
NIHSS)/Admittance NIHSS).
Statistical analysis

Two patients had significantly smaller infarct volumes
(448 mm3 and 560 mm3 compared to mean of 56,919
mm3) and edema volumes (0 mm3 and 220 mm3 compared to mean of 60,529 mm3) than the rest of the
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patient population. These two subjects were found to be
statistical outliers with high leverage values and were removed from t tests, correlations, and linear regression
analyses, and are not reported in the demographics section. For all analyses conducted in this study except the
robust regression, N=40. Since robust regression takes
into account the outliers and their influence on statistical outputs, these analyses were conducted with all 42
subjects (see below for details). Independent sample t
tests were used to investigate relationships between
VCAM1 expression and categorical variables. Correlation coefficients were used to assess the relationship between VCAM1 expression and continuous outcomes.
Due to a non-normal distribution, both infarct and
edema volume were log transformed to achieve normality. NIHSS data were analyzed in two separate ways.
First, t tests were conducted for NIHSS on admittance
relative to the median NIHSS admittance score, which
was 18. NIHSS on discharge was treated similarly relative to a median of 9. In addition to these analyses,
NIHSS was also broken down into 4 statistical quartiles
each containing 10 subjects. From lowest to highest,
these quartiles were labeled as “mild stroke,” “mild to
moderate stroke,” “moderate to severe stroke,” and “severe stroke.”
A multiple linear regression-based approach was used
to determine the network of proteins predictive of infarct and edema volume. Regression diagnostics determined the presence of several outliers for infarct and
edema volume, as well as high leverage values for some
of the proteins. To account for this, robust regression
with MM estimation was used. In this method, observations with high outliers and leverage values are given less
weight in the analysis allowing for data analysis on all 42
subjects. In order to determine the set of proteins accounting for the most variability in infarct and edema
volume, a forward selection approach was used. In the
first step, VCAM1 was entered as a predictor. In the
subsequent steps, the protein with the next strongest association with infarct or edema volume was entered,
until 10 additional proteins were selected. A final model
using these 11 proteins was then assessed. Some rules of
thumb suggest that the number of subjects per variable
in linear regression models should be between five and
twenty to avoid overfitting the model. However, a recent
simulation study found that low bias and accurately estimated standard errors can be achieved with as little as
two subjects per variable [18]. For the current study, a
subject per variable ratio of over 4 was determined to
mitigate the risk of overfitting. Network analysis was
performed on STRING V11 (https://string-db.org/)
using protein-protein interaction analysis data. All statistical analyses were performed using SAS v 9.4 (SAS Institute Inc., Cary, NC) or IBM SPSS Statistics.
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Results
Patient characteristics

Subject demographic data are shown in Table 1. There
were 40 adult (>18 years of age) subjects included in the
study with a median age of 67 (25-96), of which 24
(60%) were female. Sixteen subjects had a normal body
mass index (BMI), 17 were overweight, and 7 were
obese. Of note, 10 (26%) were current smokers, and 6
(16%) were previous smokers. According to the National
Institutes of Health Stroke Score (NIHSS), on admission,
1 (3%) of the patients had a minor stroke (NIHSS 1-4),
15 (38%) were considered to have a moderate stroke
(NIHSS 5-15), 11 (28%) were considered to have a moderate/severe stroke (NIHSS 16-20), and 12 (31%) were
considered to have a severe stroke (NIHSS > 21). On
discharge, 13 (34%) were considered to have a minor
stroke, 17 (45%) were considered to have a moderate
stroke, 5 (13%) were considered to have a moderate/severe stroke (NIHSS 16-20), and 3 (8%) were considered
to have a severe stroke (NIHSS > 21). The mean last
known normal (LKN) to thrombectomy completion time
was 639 + 367 min and the mean infarct volume was 56,
739 + 74,880 mm3.
VCAM1 and comorbidities

In our cohort of ELVO ischemic stroke patients, proteomic expression of systemic and intracranial VCAM1
was studied relative to patient sex and comorbid conditions such as hypertension, dyslipidemia, and smoking
status. Increased levels of systemic VCAM1 were significantly related to the presence of HTN (mean without
HTN = 5.17, SD = 0.28, mean with HTN = 5.80, SD =
0.50, and p value = <0.001). Similarly, increased levels of
intracranial VCAM1 were significantly related to the
presence of HTN (mean without HTN = 5.06, SD =
0.30, mean with HTN = 5.54, SD = 0.70, and p value =
0.005). We found no significant relationship with hyperlipidemia and systemic (p=0.111) or intracranial (p=
0.091) VCAM1. There were also no significant relationships between systemic or intracranial VCAM1 expression levels and whether or not the patient was a smoker
(p=0.962 and p=0.841, respectively). Finally, there were
also no significant relationships when looking at sex versus systemic VCAM1 (p=0.632) or intracranial VCAM1
(p=0.754).
VCAM1 versus stroke severity and functional recovery
after thrombectomy

Correlations between VCAM1 and infarct volume and
edema volume can be found in Fig. 1a-d. Intracranial
VCAM1 was positively correlated to both infarct volume
(p=0.032; r=0.34) and edema volume (p=0.026; r=0.35).
Systemic VCAM1 was found to have near-significant
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Table 1 Demographics and characteristics for thrombectomy
subjects (N=40)
Value (%)
Age (median; range)

67 (25-96)

Sex
Female

24 (60)

Male

16 (40)

BMI
<24.9

16 (40)

25-29.9

17 (42.5)

30-39.9

7 (17.5)

>40

0 (0)

Comorbidities
Hypertension

28 (70)

Diabetes mellitus II

9 (22.5)

Hyperlipidemia

11 (27.5)

Previous stroke

8 (20)

Smoking status**
Never

22 (58)

Currently

10 (26)

Previously (> 6 months)

6 (16)

NIHSS on admission*
Minor stroke (1–4)

1 (3)

Moderate stroke (5–15)

15 (38)

Moderate/severe (16–20)

11 (28)

Severe stroke (≥ 21)

12 (31)

NIHSS at discharge**
Minor stroke (1–4)

13 (34)

Moderate stroke (5–15)

17 (45)

Moderate/severe (16–20)

5 (13)

Severe stroke (≥ 21)

3 (8)

TICI Score
2A = < 50% perfusion

1 (2.5)

2B = > 50% perfusion

20 (50)

3 = full perfusion

19 (47.5)

LKN to thrombectomy
Completion time (minutes)**
3

Infarct volume (mm )

639.87 + 367
56,739 + 74,880

CTA collateral score**
0

8 (21)

1

24 (63)

2

5 (13)

3

1 (3)

Values are median with range, mean ± SD, or (%)
N=40 patients
*1 patient’s data missing (n=39)
**2 patient’s data missing (n=38)
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positive correlations with both infarct volume (p=0.07;
r=0.28) and edema volume (p=0.09; r=0.27).
The %Δ in NIHSS from admittance to discharge was
found to be significantly correlated to both systemic (p=
0.013; r = −0.409) and intracranial (p=0.011; r = −0.421)
VCAM1 levels indicating elevated levels of systemic and
intracranial VCAM1 are associated with reduced improvement of stroke severity based on NIHSS from admittance to discharge (data not graphed). Intracranial
and systemic VCAM1 levels were also assessed based on
median NIHSS on admittance and discharge. The median NIHSS for admission was 18 and median NIHSS
for discharge was 9. On admission, relative to a median
NIHSS of 18, those with NIHSS > 18 had higher systemic VCAM1 levels as compared to the systemic
VCAM1 levels in subjects with NIHSS admittance score
<18 (mean for NIHSS >18 = 5.8, SD = 0.68; mean for
NIHSS <18 = 5.4, SD = 0.27; p value = 0.059). Those
with NIHSS >18 had higher intracranial VCAM1 levels
as compared to the intracranial VCAM1 levels in subjects with NIHSS admittance score <18 (mean NIHSS
for >18 = 5.6, SD = 0.76; mean NIHSS <18 = 5.2, SD =
0.44; p value = 0.058). Although near-significant, admission data did not reach p value <0.05. On discharge,
however, relative to a median NIHSS of 9, those with
NIHSS >9 had significantly higher systemic VCAM1
levels as compared to the systemic VCAM1 levels in
subjects with NIHSS discharge score <9 (mean for NIHS
S >9 = 5.8, SD = 0.47; mean for NIHSS <9 = 5.4, SD =
0.53; p value = 0.009). No significant relationship was
identified for intracranial VCAM1 levels and discharge
NIHSS. Lastly, the relationship between VCAM1 and
NIHSS was also assessed by breaking our cohort into
statistical quartiles. The 10 subjects with the lowest
NIHSS scores (mild stroke category) were compared to
the 10 subjects with the highest NIHSS scores (severe
stroke category). Systemic VCAM1 levels were found to
be significantly higher in the severe stroke quartile as
compared to the mild stroke quartile (mean for mild =
5.4, SD = 0.22; mean for severe = 5.7, SD = 0.43; p value
= 0.024). We found no significant relationship with
intracranial VCAM1 levels (mean for mild = 5.2, SD =
0.45; mean for severe = 5.5, SD = 0.43; p value = 0.181).
Finally, in our cohort of subjects, there were no significant relationships between either systemic or intracranial
VCAM1 and infarct time (time from last known normal)
with p=0.145 and p=0.404, respectively.
VCAM1 and signaling proteins

All protein names and functions are directly extracted
from Olink and STRING and are provided in Supplemental Table 1. Systemic VCAM1 was significantly correlated to both systemic interleukin 6 (IL-6) as well as
intracranial IL-6 (p=0.006 and p=0.001, respectively).
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Fig. 1 Spearman correlations for VCAM1 and infarct volume and edema volume. a SystemicVCAM1 levels vs. infarct volume log2 transformed (p=
0.07; r=0.28). b Intracranial VCAM1 levels vs. infarct volume log2 transformed (p=0.032; r=0.34). c Systemic VCAM1 levels vs. edema volume log2
transformed (p=0.09; r=0.27). d Intracranial VCAM1 levels vs. edema volume log2 transformed (p=0.026; r=0.35)

Intracranial VCAM1 was significantly correlated to
intracranial IL-6 but not systemic IL-6 (p=0.003 and p=
0.098, respectively).
Robust regressions were used to determine systemic
and intracranial proteins most predictive of infarct volume and edema volume in the context of VCAM1. The
top 10 most predictive proteins identified by each model
are shown in Table 2. The R2 values for the four predictive models were systemic proteins and infarct volume
R2= 0.7551, intracranial proteins and infarct volume R2=
0.6665, systemic proteins and edema volume R2=0.6396,
and intracranial proteins and edema volume R2=0.6564.
The 10 proteins identified by each predictive model
were used as the input for STRING analysis. STRING
analyses report physical and functional associations between proteins by utilizing genome-wide proteomic connectivity integrations. STRING network webs based on
systemic and intracranial predictors of infarct volume
and edema volume are shown in Fig. 2. STRING-generated functional descriptions and associated proteins are
shown in Table 3. This table illustrates the top 10 network functions for each predictive model along with the
corresponding proteins for each specific function.

Ranking of functions into top 10 was done based on
smallest false discovery rates (FDRs).

Discussion
VCAM1 is a vascular adhesion molecule induced by several mediators including pro-inflammatory cytokines like
TNFα, reactive oxygen species (ROS), turbulent blood
flow, microbial stimulation of toll-like receptors, high
glucose concentrations, and shear stress [19–23]. Activation for binding of leukocytes with VCAM1 relies on
local microenvironmental factors including chemokine
profile and has been shown to play a role in endothelial
integrity and function in pathological states, such as atherosclerosis [24–30]. Similar to cardiovascular events,
studies have investigated the role of VCAM1 in cerebrovascular events including ischemic stroke. In this study,
we take a novel approach by sampling both intracranial
and systemic VCAM1 from human patients during
ELVO stroke to investigate how it relates to comorbid
conditions, stroke severity, functional recovery, and
protein-protein signaling pathways.
Soluble VCAM1 has been reported to be a biomarker
of endothelial dysfunction associated with both
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Table 2 Proteins with strongest predictive value for infarct
volume or edema volume based on location of blood sample.
For directionality, if the relationship is positive, higher
expression levels of that protein is associated with higher
infarct/edema volume. If the relationship is negative, higher
levels of that protein are associated with lower infarct/edema
volume. Included in the table are R2 values for each predictive
model
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Table 2 Proteins with strongest predictive value for infarct
volume or edema volume based on location of blood sample.
For directionality, if the relationship is positive, higher
expression levels of that protein is associated with higher
infarct/edema volume. If the relationship is negative, higher
levels of that protein are associated with lower infarct/edema
volume. Included in the table are R2 values for each predictive
model (Continued)
Protein

p value

Directionality

Systemic blood and infarct volume R =0.7551

F7

<0.0001

(−)

APOM

<0.0001

(−)

MBL2

0.0001

(−)

MMP10

0.0006

(+)

CSF1

0.0045

(−)

0.0012

(−)

0.0261

(+)

Protein

p value

Directionality
2

DPP4

<0.0001

(−)

CCL11

CST3

<0.0001

(−)

IL15RA

IL10RB

<0.0001

(+)

AOC3

0.0191

(+)

CXCL9

<0.0001

(+)

VASN

0.0009

(+)

IL20RA

0.0038

(+)

IL18

0.0182

(+)

Intracranial blood and infarct volume R2=0.6665
SLAMF1

<0.0001

(+)

CCL18

<0.0001

(+)

NCAM1

<0.0001

(+)

LILRB2

0.0359

(−)

CD59

<0.0001

(+)

IGFBP6

<0.0001

(−)

ANG

<0.0001

(−)

MEGF9

0.0087

(−)

MCP1

0.0001

(−)

ITGAM

0.0053

(−)

Systemic blood and edema volume R2=0.6396
APOM

0.0014

(−)

MMP10

0.0014

(+)

NT3

<0.0001

(−)

PDL1

<0.0001

(−)

SLAMF1

<0.0001

(+)

CCL5

<0.0001

(+)

ANG

<0.0001

(−)

CHL1

<0.0001

(−)

ITGAM

<0.0001

(−)

CCL25

<0.0001

(+)
2

Intracranial blood and edema volume R =0.6564
CCL18

<0.0001

(+)

SLAMF1

<0.0001

(+)

FAP

<0.0001

(−)

PDL1

<0.0001

(−)

TSLP

0.1851

(+)

hypertension and atherosclerosis [27, 31–34]. Increased
levels of soluble VCAM1 have been observed in patients
with primary hypertension and VCAM1 levels have been
shown to be reduced after antihypertensive therapy [35–
38]. Tchalla et al. studied levels of circulating soluble
VCAM1 in an adult population and reported elevated
levels may serve as a marker of blood flow dysregulation
due to hypertension-induced endothelial damage [31].
Within our cohort, those with HTN had significantly
higher levels of both intracranial and systemic VCAM1
when compared to those without HTN, further supporting this relationship. Interestingly, our data demonstrate
that the relationship between HTN and VCAM1 is not
only limited to systemic arterial circulation but is also
found locally at the site of infarct. VCAM1 is a key
player in facilitating atherosclerosis by aiding in the local
attachment and transmigration of inflammatory cells
through the vascular endothelium [39–42]. Interestingly,
we found no significant relationship between systemic or
intracranial VCAM1 levels and the presence of hypercholesterolemia. Other comorbid conditions have also
been reported; for example, in a population with coronary artery disease, levels of soluble VCAM1 were significantly higher in those who smoked as compared to
those who did not [43] though in our ELVO cohort we
found no significant relationship with VCAM1 levels
and smoking status.
The Chongqing Stroke Study reported that ischemic
stroke patients with neurological deterioration had
higher levels of soluble ICAM1 but not soluble VCAM1
compared to patients without neurological deterioration
based on the NIHSS [44]. Another study reported increased levels of VCAM1 in patients with thromboembolic stroke compared to controls [1]. In that study,
there was no significant correlation between levels of
soluble VCAM1 and stroke severity or disability based
on NIHSS conducted at time of blood sampling (within
24 h of stroke symptom onset). Blum et al. investigated
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Fig. 2 STRING protein-protein network analyses for (a) systemic VCAM1 and infarct volume, (b) intracranial VCAM1 and infarct volume, (c)
systemic VCAM1 and infarct edema volume, and (d) intracranial VCAM1 and infarct edema volume

the association between NIHSS on admission and 4 days
later with levels of cell adhesion molecules in acute ischemic patients [45]. They reported that in 19 out of 23
patients who improved after an acute cerebral event,
there was a significant decrease in the NIHSS which was
accompanied by a significant decrease in the cell adhesion molecules E-selectin, ICAM1, and VCAM1. In contrast to our results, those data demonstrate that for
patients who experienced clinical improvement in the
first few days after insult, the expression of cell adhesion
molecules was reduced.
Our study assessed NIHSS in three ways. First, we analyzed the relationship between systemic and intracranial VCAM1 levels on NIHSS at admission and
discharge separately, based on their respective median
NIHSS. We found that increased levels of systemic
VCAM1 was significantly associated with a higher
NIHSS on discharge. Increased levels of intracranial
VCAM1 were also found to be related to higher NIHSS
on discharge, however, this was not significant. Additionally, increased levels of both systemic and

intracranial VCAM1 were related to higher NIHSS on
admittance; however, these values did not reach statistical significance (p=0.059 and p=0.058, respectively).
Secondly, we looked at VCAM1 expression levels as
they relate to the %ΔNIHSS by linear regression analysis. We used %ΔNIHSS to capture the improvement
in stroke severity between admittance and discharge.
We found that both systemic and intracranial VCAM1
levels were significantly higher in subjects with the
smallest %ΔNIHSS revealing that higher VCAM1 levels
is positively correlated with poorer functional recovery
after thrombectomy. Lastly, we used statistical quartiles
to compare the 10 mildest stroke deficits based on
NIHSS with the 10 most severe strokes injuries based
on NIHSS. We found that increased levels of systemic
VCAM1 were significantly higher in the severe category
compared to the mild category. In comparison to Blum
et al., our study differs as it captures infarct in-progress
data rather than in the recovery phase.
It has also been reported that in patients with acute
cerebral ischemia, plasma levels of VCAM1 can remain
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Table 3 Network functions and associated proteins
Term ID Biological process

Strength False
discovery
rate

Matching proteins in network

GO:
Cytokine-mediated signaling pathway
0019221

1.25

1.87E−07

IL10RA, IL18RAP, IL18, IL10RB, IL20RA, IFNLR1, CXCL9, CXCR3, CASP1

GO:
Cellular response to chemical stimulus
0070887

0.8

1.89E−07

IL10RA, IL18RAP, IL18, IL10RB, VASN, AOC3, IL20RA, IFNLR1, CXCL9,
CXCR3, APOM, CST3, CASP1

GO:
Defense response
0006952

1.02

6.16E−07

IL18RAP, IL18, IL10RB, AOC3, IFNLR1, DPP4, CXCL9, CXCR3, CST3,
CASP1

GO:
Response to organic substance
0010033

0.71

4.92E−05

IL10RA, IL18RAP, IL18, IL10RB, IL20RA, IFNLR1, CXCL9, CXCR3, APOM,
CST3, CASP1

GO:
Inflammatory response
0006954

1.21

9.58E−05

IL18RAP, IL18, IL10RB, AOC3, CXCL9, CXCR3

GO:
Response to stress
0006950

0.64

0.00018

IL18RAP, IL18, IL10RB, VASN, AOC3, IFNLR1, DPP4, CXCL9, CXCR3,
CST3, CASP1

GO:
Cytokine production
0001816

1.58

0.00026

IL18RAP, IL18, CXCR3, CASP1

GO:
Negative regulation of extracellular
0010716 matrix disassembly

2.81

0.00056

DPP4, CST3

GO:
T-helper 1 cell cytokine production
0035744

2.81

0.00056

IL18RAP, IL18

GO:
Immune system process
0002376

0.69

0.00076

IL18RAP, IL18, IL10RB, IFNLR1, DPP4, CXCL9, CXCR3, CST3, CASP1

A. Systemic VCAM1 and infarct volume network

B. Intracranial VCAM1 and infarct volume networks
GO:
Positive regulation of leukocyte
0002696 activation

1.52

4.66E−08

CCL2, CCR2, VCAM1, LILRB2, IGF2, IL10, HLA-G, ITGAM

GO:
Immune response
0006955

0.97

4.66E−08

CCL2, CCR2, VCAM1, SLAMF1, ANG, LILRB2, CD59, IL10, HLA-G, ITGA
M, CCL18, NCAM1

GO:
Defense response
0006952

1.04

6.64E−08

CCL2, CCR2, VCAM1, SLAMF1, ANG, LILRB2, IL10, HLA-G, ITGAM,
CCL18, NCAM1

GO:
Positive regulation of cell-cell adhesion
0022409

1.56

1.14E−07

CCL2, CCR2, VCAM1, LILRB2, IGF2, IL10, HLA-G

GO:
Regulation of leukocyte cell-cell
1903037 adhesion

1.49

2.67E−07

CCL2, CCR2, VCAM1, LILRB2, IGF2, IL10, HLA-G

GO:
Regulation of T cell proliferation
0042129

1.69

2.81E−07

CCR2, VCAM1, LILRB2, IGF2, IL10, HLA-G

GO:
Regulation of T cell activation
0050863

1.45

3.15E−07

CCL2, CCR2, VCAM1, LILRB2, IGF2, IL10, HLA-G

GO:
Response to other organism
0051707

1.02

4.04E−07

CCL2, VCAM1, SLAMF1, ANG, LILRB2, IL10, HLA-G, ITGAM, CCL18,
NCAM1

GO:
Defense response to other organism
0098542

1.11

4.87E−07

CCL2, VCAM1, SLAMF1, ANG, IL10, HLA-G, ITGAM, CCL18, NCAM1

GO:
Positive regulation of T cell activation
0050870

1.58

6.23E−07

CCL2, CCR2, VCAM1, LILRB2, IGF2, HLA-G

C. Systemic VCAM1 and edema volume networks
GO:
Immune response
0006955

0.94

2.65E−06

CCR5, VCAM1, CXCL10, SLAMF1, PDCD1, ANG, CCR9, CD274, CCL25,
ITGAM, CCL5

GO:
Chemokine-mediated signaling
0070098 pathway

1.91

2.65E−06

CCR5, CXCL10, CCR9, CCL25, CCL5

GO:
Chemotaxis
0006935

1.24

1.28E−05

CHL1, CCR5, VCAM1, CXCL10, CCR9, CCL25, CCL5

GO:
Defense response
0006952

0.95

1.28E−05

CCR5, VCAM1, CXCL10, SLAMF1, ANG, CCR9, CCL25, ITGAM, CCL5
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Table 3 Network functions and associated proteins (Continued)
Term ID Biological process

Strength False
discovery
rate

Matching proteins in network

GO:
Cell migration
0016477

1.08

1.28E−05

CHL1, CCR5, VCAM1, CXCL10, ANG, CCL25, ITGAM, CCL5

GO:
Locomotion
0040011

0.98

1.28E−05

CHL1, CCR5, VCAM1, CXCL10, ANG, CCR9, CCL25, ITGAM, CCL5

GO:
Leukocyte migration
0050900

1.39

1.28E−05

CCR5, VCAM1, CXCL10, CCL25, ITGAM, CCL5

GO:
Cell chemotaxis
0060326

1.52

2.29E−05

CCR5, VCAM1, CXCL10, CCL25, CCL5

GO:
Positive regulation of T cell apoptotic
0070234 process

2.39

2.50E−05

PDCD1, CD274, CCL5

GO:
Cytokine-mediated signaling pathway
0019221

1.12

2.77E−05

CCR5, VCAM1, CXCL10, CCR9, CCL25, ITGAM, CCL5

D. Intracranial VCAM1 and edema volume networks
GO:
Cytokine-mediated signaling pathway
0019221

1.27

1.07E−08

CSF1R, VCAM1, CCL11, CSF1, F3, TSLP, IL15RA, CRLF2, CCR3, CCL18

GO:
Response to cytokine
0034097

1.11

1.38E−08

CSF1R, VCAM1, CCL11, CSF1, F3, TSLP, CD274, IL15RA, CRLF2, CCR3,
CCL18

GO:
Positive regulation of cell population
0008284 proliferation

1.14

6.15E−08

CSF1R, VCAM1, CCL11, SLAMF1, CSF1, F3, TSLP, CD274, CRLF2, CCR3

GO:
Inflammatory response
0006954

1.31

2.65E−07

CSF1R, VCAM1, CCL11, CSF1, F3, MBL2, CCR3, CCL18

GO:
Regulation of cell population
0042127 proliferation

0.93

4.53E−07

FAP, CSF1R, VCAM1, CCL11, SLAMF1, CSF1, F3, TSLP, CD274, CRLF2,
CCR3

GO:
Defense response
0006952

1

7.01E−07

CSF1R, VCAM1, CCL11, SLAMF1, CSF1, F3, TSLP, MBL2, CCR3, CCL18

GO:
Positive regulation of cellular process
0048522

0.57

1.25E−06

FAP, CSF1R, VCAM1, CCL11, SLAMF1, CSF1, F3, PDCD1, TSLP, MBL2,
F7, CD274, CRLF2, CCR3, CCL18

GO:
Positive regulation of intracellular signal 1.06
1902533 transduction

1.33E−06

CSF1R, CCL11, SLAMF1, CSF1, F3, TSLP, F7, CRLF2, CCL18

GO:
Positive regulation of response to
0048584 stimulus

0.82

3.90E−06

CSF1R, CCL11, SLAMF1, CSF1, F3, TSLP, MBL2, F7, CD274, CRLF2,
CCL18

GO:
Immune response
0006955

0.89

4.19E−06

CSF1R, VCAM1, CCL11, SLAMF1, CSF1, PDCD1, TSLP, MBL2, CD274,
CCL18

STRING Term ID provided in the first column. Top 10 biological functions for each network based on smallest false discovery rate (FDR) listed in second column.
Analysis strength and FDR listed in columns 3 and 4, respectively. Column 5 lists function-related proteins for each biologic process. Table is broken down by
network: (A) Systemic VCAM1 and infarct volume network, (B) Intracranial VCAM1 and infarct volume network, (C) Systemic VCAM1 and infarct edema volume
network, and (D) Intracranial VCAM1 and infarct edema volume network

elevated over a 3-month period, showing a protracted
inflammation in patients who have experienced cerebrovascular disease [10]. A longitudinal prospective study
on soluble adhesion molecules after cerebral infarction
reported that soluble VCAM1 reached its maximum
plasma levels at 5 days after stroke [46]. We chose to investigate whether or not VCAM1 levels were correlated
with infarct time (time from last known normal) and
interestingly found no significant relationships. However,
this may be due to the narrower window of time in
which a thrombectomy occurs after the onset of occlusion as compared to a 3-month period used in other
studies. These results demonstrate that levels of VCAM1
in our cohort are not dependent on infarct time,

although comorbid inflammatory conditions may affect
this timeline. Our data provide an acute snapshot of the
in-progress infarct rather than the recovery phase after
stroke. Taken together, these studies provide insight into
the timeline of VCAM1 activation/inactivation in the
acute event as well as in the post-stroke recovery time
and how that directly affects stroke severity and recovery. Of note, our study investigated solely ELVOs in subjects during their stroke undergoing thrombectomy,
whereas several prior studies capture data on a broader
population with a variety of ischemic insults including
ELVO [10, 46].
The goal of recanalization after stroke is to minimize
tissue death and salvage penumbra by reducing infarct
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volume. Past studies demonstrated final infarct volume
may be used as a surrogate marker of functional outcome and recovery [47, 48]. To our knowledge, we are
the first group to demonstrate the relationship between
VCAM1 and both infarct volume and edema volume as
intracranial VCAM1 levels were significantly predictive
of both infarct volume and edema volume. Although
non-significant, increased systemic levels of VCAM1
were also related to infarct volume and edema volume.
These data may reflect the consequences of endothelial
dysfunction and damage as they relate to a direct measure of stroke severity and outcome. In addition, these
data may assist in predicting treatment modalities such
as the need for decompressive hemicraniectomies due to
strokes with large infarct and edema volumes.
One of the main objectives of this study was to investigate VCAM1 in context to proteomic signaling networks. First, we wanted to compare our VCAM1 data to
a well-known and well-reported inflammatory cytokine,
IL-6. It has been shown that higher levels of circulating
IL-6 are associated with stroke risk factors and increased
risk of stroke [16)]. For example, a previous study demonstrated that hypomethylation of IL-6 gene increases
the risk of essential hypertension [49]. Our study found
systemic VCAM1 was significantly related to both systemic and intracranial IL-6 and that intracranial VCAM1
was significantly related to intracranial IL-6. Our study
also reports significant relationships between VCAM1
and HTN, which may corroborate the interplay between
IL-6 and VCAM1 with HTN. Additionally, peak plasma
levels of IL-6 in the first week of ischemic stroke significantly related to infarct volume at 5-7 days post-stroke,
as well as clinical outcome at 3 months [17]. Our data
supports existing literature and adds to it by providing
data on intracranial levels and potential intracranial relationships of IL-6 with VCAM1.
To further address the objective of uncovering signaling networks, robust regression and STRING analyses
were utilized. Robust regressions identified systemic and
intracranial proteins related to VCAM1 that were most
predictive of infarct volume and edema volume. Once
identified, these proteins were used as the input for
STRING analysis. The STRING database allows investigators to explore physical and functional associations between proteins by utilizing genome-wide proteomic
connectivity integrations focused on a specific biological
process of interest [50]. Publications based on STRING
demonstrate the utility for synthesizing text mining and
experimental evidence to provide probabilities of viral
and proteomic interactions [51]. These analyses uncover
functions of relevant network pathways and provide information on biological predictors which are of particular interest to our research goal. From STRING, we
captured the top 10 biologic functions for each network
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analyzed shown in Table 3. Common biological functions included “immune response,” “defense response,”
“cytokine-mediated signaling pathway,” and “regulation
of T cell activation.” These functions provide a useful
snapshot of the biologic processes underway in both systemic and intracranial arterial blood at the time of
mechanical thrombectomy.
For each VCAM1 network, some proteins were associated with all of the top 10 biological functions. For example, for the intracranial VCAM1 and infarct volume
network, C-C motif chemokine ligand 2 (CCL2) was associated with each of the top 10 biological functions of
that network. Prior literature demonstrated that genetic
predisposition to higher levels of CCL2 is associated
with higher risk of ischemic stroke [52]. Further, a recent study also found elevated CCL2 expression in a rat
model of middle cerebral artery occlusion, and when
CCL2 inhibitors were administered, there was a significant reduction in the inflammatory response and neurological impairment [53]. Our findings support these
studies by reporting intracranial data along with networks of associated proteins that are related to objective
clinical measures such as infarct volume.
Intracranial and systemic sampling of arterial blood at
the time of thrombectomy provides an interesting
physiologic/pathologic snapshot of ischemic stroke.
Moreover, understanding the local microenvironment at
the lesion site may allow therapeutics to be developed
for intracranial administration during the thrombectomy. As increased VCAM1 levels were predictive of infarct volume and edema volume, future studies will aim
to reverse translate these results into experimental
stroke models with intention of neutralizing VCAM1 in
the acute phase of ischemic stroke. Our study offers
many starting points for analyses similar to Li et al.
which utilize reverse translation for development of
therapeutics [53]. In this study, we also used a model to
identify protein-protein networks that were predictive of
infarct volume and infarct edema. These data provide
insight into the larger picture of signaling pathways and
physiologic functions that may predict stroke severity
and further our understanding of stroke diagnostics and
prognostics. In addition, these data provide practical
therapeutic targets for drug development and drug repurposing and will be the focus of future translational
studies.
One limitation of our study is the sample size. After
exclusion, we studied proteomic data from 40 stroke
subjects. Thus, this is a preliminary study that will be
validated with increasing enrollment into our tissue bank
and registry. Although we found significance in many of
our analyses, there are potential confounding variables
as well as inherent heterogeneity which may act to limit
conclusions. These include the spectrum of stroke
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severity, ischemic injury timeline, and comorbid conditions. In addition, we must also be aware of potential
variations in basal level of protein expression and proteases for each subject. Another potential limitation to our
cohort is the larger proportion of female as compared to
male subjects. Sex differences are well known in stroke
and an expanding study population will help address this
discrepancy in our patient demographics [54]. Lastly,
this study is limited by its geographic location. Our hospital in Central Kentucky serves a population primarily
Caucasian with comorbidities common to the region.
Many of these limitations highlight the utility of multiinstitutional/multi-national collaborations. As our
thrombectomy registry grows and collaborations develop, we will be able to combat the variances and limitations in these data as well as conduct subset statistical
analyses with larger power and generalizability.
With data on 40 subjects, one potential critique is that
this study suffered from low power when investigating
differences in VCAM1 expression by comorbidities. Assuming the comorbidities were evenly distributed
throughout the sample, this study had 80% power to detect a Cohen’s d effect size of 0.90 using a two tailed t
test where α = .05. According to conventional cutoffs,
this represents a large effect. Thus, it should not be assumed that comorbidities with non-significant VCAM1
differences reported here are not different in the population—this study was not powered to find differences in
the small to medium range. Future studies utilizing larger samples will be helpful in determining how VCAM1
expression differs according to the presence of
comorbidities.

Conclusion
The current study provides novel data on systemic and
intracranial VCAM1 in relation to stroke comorbidities,
stroke severity, and recovery, as well as the role VCAM1
plays in complex protein-protein signaling pathways.
These data will allow future studies to reverse translate
into animal models for drug development. This study
also serves as an example of how contemporary analytical tools from human data can be utilized to better predict stroke as well as uncover novel targets for much
needed therapeutics.
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